(WHO) 2008 global report on tuberculosis, 700,000 of the 9.2 million new tuberculosis cases reported in 2006 occurred among HIV-infected people [4] . HIV has an effect on the incidence, prevalence, clinical presentation, diagnostic yield, and treatment options for patients with tuberculosis. The developing world has the highest burden of both diseases [5] .
India has 20% of the global burden of tuberculosis infections, with 1.8 million new cases each year, as well as a large pool (∼2.5 million) of HIV-infected individuals [4, 5] . This sets the stage for a deadly synergy between the 2 infections. The risk of developing tuberculosis disease for HIV-infected patients in India is estimated to be 7 cases per 100 person-years at risk, compared with the 10% lifetime risk of an immunocompetent host [6] . Even though the initial bacteriologic response to antituberculosis therapy is similar in both HIV-infected and HIV-uninfected patients, recurrences of tuberculosis infection are more frequent among coinfected patients, especially in countries with high rates of tuberculosis infection [7] . Recurrences of tuberculosis could be due to either exogenous reinfection or endogenous reactivation, and the 2 can be differentiated by molecular typing. For decades, the issue of the role played by exogenous reinfection versus endogenous reactivation has been debated [8, 9] . We have earlier shown that endogenous reactivation predominates in patients with tuberculosis not infected with HIV [10] . However, there are no data with regard to HIVcoinfected patients with tuberculosis from India and limited data from other parts of the world [11, 12] . It is likely that the presence of HIV in communities could modify the pattern of tuberculosis transmission.
There are several genotyping tools, including restriction fragment length polymorphism (RFLP) typing, spoligotyping, and mycobacterial interspersed repeat unit (MIRU)-variable number tandem repeat (VNTR) typing that are used to differentiate tuberculosis strains. Each of these techniques has its own advantages and disadvantages. It is preferable to use more than 1 method to accurately assess the source of the tuberculosis strain that is infecting patients. In the present study, we compared the relative proportions of reinfection or reactivation among recurrence isolates of M. tuberculosis from HIV-infected and HIV-uninfected patients enrolled in clinical trials and followed up at the Tuberculosis Research Centre (TRC), Chennai, India. All patients were well characterized at baseline, treated under similar conditions with short-course regimens, and followed up regularly to document treatment outcomes. Our aims were to study the role of HIV infection in tuberculosis transmission in a tuberculosis-endemic setting and also the relative performance of the 3 genotypic methods in classifying strains.
METHODS
Study population and setting. The study was conducted at the TRC's clinics in Chennai and Madurai, South India, from July 1999 to October 2005. The Institutional Ethics committee had approved the clinical trials, and all patients provided written informed consent. Patients were evaluated for the presence of HIV and tuberculosis, as well as their suitability for clinical trials. A standardized questionnaire was administered by a physician, clinical examination was performed, and a chest radiograph was taken. HIV infection was diagnosed on the basis of 3 tests: samples found positive using the TRIDOT rapid test (J Mitra) were next tested with CombAids (Span Diagnostics, India), followed by an enzyme-linked immunosorbent assay (Lab Systems, India). Tuberculosis was suspected on the basis of clinical and radiographic features, and diagnosis was confirmed by mycobacterial culture.
Patients were recruited for clinical trials if they fulfilled the clinical and laboratory eligibility criteria. HIV-infected patients included in this analysis were from a pilot study of 6-month short-course treatment and a randomized clinical trial comparing 6 and 9 months of treatment (NCT 00376012). Patients received a standard short-course antituberculosis regimen consisting of ethambutol (1200 mg), isoniazid (600 mg), rifampin (450 or 600 mg for patients weighing !60 or 160 kg, respectively), and pyrazinamide (1500 mg) thrice-weekly for the initial 2 months (intensive phase, 2EHRZ 3 ), followed by rifampin and isoniazid thrice-weekly for the next 4 or 7 months (continuation phase, 4/7RH 3 ) [13] . All doses in the intensive phase and 1 dose per week in the continuation phase were directly observed. Surprise pill counts at home, urine tested for acetylisoniazid, and return of empty pill covers were done to check adherence. Patients included in the efficacy analysis had adherence 180%, and most of the bacteriologic recurrences came from this group. Patients did not have access to antiretroviral treatment during the course of this study.
Of the 25 HIV-negative patients with recurrent disease in the study, 12 had been treated with the same short-course regimen (2EHRZ 3 /4RH 3 ) at the same dosages, whereas 11 were treated with regimens containing ofloxacin (3 months of daily isoniazid [300 mg], rifampin [450 or 600 mg, depending on the patient's weight], pyrazinamide [1500 mg], and ofloxacin [400 mg], followed by 1 or 2 months of thrice-weekly isoniazid and rifampin), as they were enrolled in a trial assessing the efficacy of fluoroquinolones [14] . Patients were reviewed clinically and with sputum examination every month up to 24 months and every 3 months thereafter, until 36 months from treatment initiation.
Bacteriologic methods. Three sputum samples were collected at baseline and every month during treatment, and 2 sputum samples were collected every month during the followup period. Sputum smears were examined for acid-fast bacillus (AFB) by fluorescence microscopy before being processed by the modified Petroff method and cultured on Lowenstein-Jensen medium for 8 weeks. Species identification was performed using standard biochemical tests and drug susceptibility tests by standard methods at the TRC, a WHO supranational reference laboratory for mycobacteria [15] .
Molecular typing methods. Genomic DNA was extracted from M. tuberculosis cultures by standard cetyltrimethyl ammonium bromide (CTAB)-NaCl extraction method [16] . IS6110 DNA fingerprinting was done according to internationally accepted guidelines [17] . Spoligotyping was performed using standard methods [18] . In brief, the spacers between the direct repeats in the target region were amplified by using a primer set, primer Dra 5 -CC AAG AGG GGA CGG AAA C-3 and biotinylated primer Drb 5 -GGT TTT GGG TCT GAC GAC-3 . The polymerase chain reaction (PCR) products were then hybridized to a Biodyne C membrane (Isogen Bioscience). This membrane contains immobilized synthetic oligomeric spacer sequences derived from the direct-repeat region of M. tuberculosis H 37 Rv and Mycobacterium bovis BCG. Hybridized DNA was detected using an enhanced chemiluminescence kit (Amersham International), with exposure to X-ray film producing a pattern or profile reminiscent of a bar code.
MIRU-VNTR genotyping was performed by using multiplex PCR, X-Rhomadine-labeled MapMarker 1000, standard size (BioVentures), and ABI 3100 and ABI 3730-XL sequencers (Applied Biosystems). Sizing of the PCR fragments and assignment of the various VNTR alleles were performed by using customized GeneScan and Genotyper (version 2.0) or Genemapper software packages (PE Applied Biosystems). All results were entered into Microsoft Excel (version 2003) in a digital format [19] . Patterns obtained by the different methods were analyzed using Bionumerics software (version 5.0; Applied Maths). Separate databases were created for both HIV-infected and HIVuninfected patients with tuberculosis, and RFLP images were scanned and loaded as the primary genotyping method. Spoligotyping and MIRU data were loaded into these databases as a character type in numerical code. These data were linked to the respective sample number so that for a single sample all 3 typing data were available for comparison. If the fingerprint patterns were identical (number and position of bands, spots, and peaks) by all 3 methods or differed by 1 band, spot, or peak, the recurrence was classified as reactivation, whereas if the patterns differed by 2 or more bands, spots, or peaks by any of the methods, the recurrence was classified as reinfection. Clustering analysis was done by similarity matrix using Jaccard coefficient, and dendrograms were drawn by unweighted pair group method using arithmetic averages (UPGMA) using Bionumerics software (Applied Maths).
Statistical Analysis. We used x 2 test with Yates continuity correction or Fisher exact test as appropriate to compare proportions. A P value of !.05 was regarded as significant.
RESULTS
In total, 387 HIV-infected patients with culture-confirmed pulmonary tuberculosis were treated, and 306 (79%) were declared cured (all sputum specimen results were negative during the last 2 months of treatment). The mean age of the patients was 34 years; mean weight was 44 kg, 77% were men, and the median CD4 count was 160 cells/mL. Of the 44 (14.4%) documented recurrences, results from all 3 genotyping methods for both time points were available for 25 patients. We compared the demographic characteristics of patients whose isolates were not typed ( ) with those patients whose isolates were n p 14 typed (
). Patients were similar in terms of age (mean, n p 15 34 and 33 years, respectively), sex distribution, weight (mean, 42.6 and 44 kg, respectively), socioeconomic status, and median viral load (257,844 and 209,227 copies/mL, respectively). Mean CD4 cell count was 220 cells/mL in patients whose isolates were typed versus 165 cells/mL in those whose isolates were not typed. During the same period, a large number of HIV-uninfected patients with pulmonary tuberculosis were treated at the TRC. Genotypic results of paired isolates using all 3 methods were available for 23 patients; their mean age was 37 years, mean weight was 42.1 kg, and 79% were men. Tables 1 and 2 show the genotyping results and drug susceptibility pattern of all patients using the 3 different methods. We found that in 22 (88%) of 25 HIV-infected patients, the recurrence was due to a new strain of tuberculosis, whereas in 21 (91%) of 23 HIVuninfected patients recurrence was due to the same strain ( ). To rule out cross-contamination as a reason for ap-P ! .05 parent exogenous reinfection, we examined serial isolates from several patients at and after recurrence and looked for consistency of results. The number of serial isolates obtained from patients ranged from 2 to 8, and all of them were concordant with their respective primary isolates. Among recurrences, 10 HIV-infected and 5 HIV-uninfected patients had isolates resistant to 1 or more drugs; 6 HIV-infected and 2 HIV-uninfected patients had isolates that were multidrug resistant. Figure 2 shows the timing of recurrence, by type and HIV status. Although most reactivation of disease tended to occur within 12 months of completion of treatment, at least half of all reinfections occurred after 12 months.
IS6110 RFLP data revealed that both groups of patients had a high proportion (45% and 47%, respectively) of IS6110 single copy M. tuberculosis isolates. There was no significant difference in the distribution of IS6110 types between the 2 groups. Eleven percent of HIV-infected and 20% HIV-uninfected patients with tuberculosis were infected with 2-5-copy strains, although no- 
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NOTE. MIRU, mycobacterial interspersed repeat unit; RFLP, restriction fragment length polymorphism; SHRE, streptomycin, isoniazid, rifampin, and ethambutol; ST, spoligotype. copy strains were rare (Figure 3 ). Figure 4 shows the spoligotyping data of isolates from HIV-infected and HIV-uninfected patients with tuberculosis at baseline and recurrence. M. tuberculosis isolates of EAI3 clade were more common among HIV-infected patients (49%) than HIV-uninfected patients with tuberculosis (38%) ( ), whereas the EAI5 clade was more P ! .05 common among HIV-uninfected patients (26% vs 18%; P ! ). The Beijing genotype was present in 4% of HIV-infected .05 patients and none of the HIV-uninfected patients.
There were 6 MIRU clusters of 2 isolates each, which were differentiated by spoligotyping or IS6110 RFLP (data not shown). Table 3 shows 4 spoligotyping and IS6110 clusters ranging from 2 to 10 isolates, which were differentiated by MIRU. Tables 4 and 5 show the clustering of strains among recurrence isolates among HIV-uninfected and HIV-infected patients, respectively. Recurrences among HIV-infected patients tended to have more clustering. The dendrograms in Figure 5A and 5B show the clustering pattern of HIV-infected and HIV-uninfected patients with tuberculosis by usable DNA recovered. The distance between the isolates represents the similarity index of individual isolates calculated by Jaccard coefficient.
DISCUSSION
The fact that persons previously infected with M. tuberculosis could be exogenously reinfected has been well documented [20] [21] [22] [23] . However, this was thought to occur rarely because of the immunity conferred by primary infection. The pandemic of HIV has modified the epidemiological profile, pathogenesis, and clinical manifestations of tuberculosis [24, 25] . Distinguishing between recurrence due to endogenous reactivation or to exogenous reinfection is essential to accurately determine the efficacy of tuberculosis treatment regimens. The contribution of recurrence to the epidemiological profile and pathogenesis of tuberculosis also has important implications for vaccine design, chemoprophylaxis, and design of national tuberculosis control programs. This distinction is particularly important in settings with high tuberculosis prevalence. In the absence of clinical or epidemiological pointers to the origin of a tuberculosis episode being due to recent or reactivated infection, molecular epidemiological analysis has played a substantial role in clarifying the issue. In this study, we have com- pared pretreatment isolates of M. tuberculosis with isolates at the time of recurrence among HIV-infected and HIV-uninfected patients with tuberculosis treated with short-course antituberculosis regimens in South India. Our objectives were to examine the role played by HIV infection in determining the type of tuberculosis recurrence (ie, relative frequency of endogenous reactivation versus that of exogenous reinfection) in a high tuberculosis prevalence setting, as well as to study the performance of 3 molecular typing methods (IS6110 RFLP, spoligotyping, and analysis of MIRU-VNTR).
In previous studies from TRC using a combination of DRand IS6110-RFLP typing, a high rate of endogenous reactivation was reported among HIV-uninfected patients with tuberculosis [26] . In contrast, in this study conducted in the same setting, we have clearly shown that the majority (88%) of recurrences among HIV-infected patients with tuberculosis are due to reinfection with a new strain of M. tuberculosis. Among HIVuninfected patients with tuberculosis during the same period, ∼9% of recurrences were due to exogenous reinfection, whereas the majority (190%) were due to endogenous reactivation. These results show that reinfection is much more common in patients with tuberculosis who are coinfected with HIV, particularly in the presence of immunosuppression. A study among South African mine workers also showed predominance of reinfection among HIV-infected (62%) and more of endogenous reactivation among HIV-uninfected patients with tuberculosis (94%) [27] , which is similar to our findings. There has been wide variability in studies involving patients with negative or unknown HIV status, with reinfection accounting for 18%-80% of recurrences in countries with low incidence of tuberculosis and 6%-80% in countries with high incidence of tuberculosis [7, 28, 29] .
The dendrogram shows 5 major clusters among tuberculosis isolates (baseline and recurrence) from HIV-infected patients and 2 clusters among HIV-uninfected patients, suggesting that the former are more heterogeneous in nature, probably because exogenous reinfection was more common. We considered the possibility that different fingerprints at various time points observed among HIV-infected patients with tuberculosis in this study could have arisen from either true new infection or misclassification. Over time, mutations or transpositions can alter the fingerprint pattern of a strain, resulting in overestimation of reinfection. We addressed this potential error by examining more than 1 isolate from the same patient at different time points after recurrence and confirming that they were identical. We also compared the DNA fingerprints of samples in 20% of the cases processed in the laboratory on the same day to rule out laboratory cross-contamination. Furthermore, strains that were clustered by MIRU were differentiated by spoligotyping and RFLP, and similarly isolates that were clustered by spoligotyping and RFLP were differentiated by MIRU. Hence, a reliable estimate of exogenous and endogenous infection could be obtained by using multiple genotyping methods to fingerprint tuberculosis clinical isolates.
We have previously reported that ∼40% of M. tuberculosis strains in South India carry a single copy of IS6110, making it difficult to use this as the sole method for typing [10] . In this study also, 45%-47% of patients were infected with a singlecopy strain, regardless of HIV status. MIRU-VNTR typing is a promising method with high discriminative characteristics that can be used to differentiate IS6110 single-copy isolates. Genotypic strategies using 2 or more PCR-based methods have been proposed for investigations into tuberculosis epidemiological profile and phylogeny [30, 31] . Spoligotyping showed that the EAI3 and EAI5 clades of M. tuberculosis are most prevalent in this region, with the Beijing strain being rare. This is similar to previous reports from South India [32] but different from clades commonly observed (type 26, Delhi type, type 54) in North India [33] .
In many countries, facilities for care and treatment of patients with HIV/AIDS and tuberculosis overlap, creating opportunities for nosocomial transmission and cross-infection. This may be one of the reasons for the high rate of exogenous reinfection seen in our study, because many of our patients had spent time in hospital wards where they could have been exposed to infectious patients with tuberculosis. Unfortunately, because of the large number of in-patients and high turnover in these hospitals, we were unable to actually prove nosocomial transmission. There is indirect evidence for this because clustering of recurrence isolates was greater among HIV-infected than HIV-uninfected patients (Tables 4 and 5 ). Recurrences among HIV-uninfected patients with tuberculosis appear to be due mainly to reactivation of mycobacteria in lesions that have been incompletely sterilized by the antituberculosis drugs, a phenomenon that is incompletely understood. In this study, half the patients had received a trial regimen of 4 or 5 months duration (with ofloxacin), whereas the other half had received the standard 6-month short-course regimen. Regardless of the regimen, almost all the recurrences were due to reactivation.
One of the limitations of our study is that not all recurrences that occurred during this period could be included, usually because either the baseline or recurrence isolate was unavailable for genetic analysis or all 3 techniques had not been used. Thus, a potential bias could have occurred as a result of selectivity of specimens studied. Furthermore, the number of patients with recurrences studied is not an indication of the overall efficacy of the regimens under trial. In fact, it is well known that recurrence rates are higher among HIV-infected patients with tuberculosis [34, 35] . In a pilot study of patients with advanced HIV and tuberculosis treated with a 6-month regimen, we observed a favorable response of 72% at the end of treatment and during 2 years of follow-up, a mortality rate of 35% and tuberculosis recurrence rate of 39% [36] . Some of the patients in the present report were participants in a randomized clinical trial comparing 6 and 9 months antituberculosis treatment, results of which have been submitted for publication separately [13] . There, we describe the outcome of tuberculosis treatment, including failures and recurrences and mention of DNA fingerprinting results. Here, we report the details of strain typing using robust molecular methods among recurrences that occurred in the HIV clinical trial and have used data from concurrently treated HIV-uninfected patients with tuberculosis for comparison. Hence, we are not comparing tuberculosis outcomes between these 2 very different groups but only the nature of recurrences.
In the ofloxacin trial among HIV-negative patients, recurrence rates ranged from 2% to 13% for the different regimens, whereas the rate for patients treated using the standard shortcourse regimen in the tuberculosis control program has been reported to be in the range of 11%-12% [14, 37] . We believe the fact that half the HIV-uninfected patients received a nonstandard antituberculosis regimen (with ofloxacin) does not change the interpretation of the results because of the overwhelming preponderance of reactivation in this group, regardless of regimen received. The strengths of this study are the concurrent nature of the 2 treatment trials and the identical setting under which they were conducted (ensuring comparability), as well as the excellent follow-up and documentation of treatment outcomes. Furthermore, we have taken care to distinguish true reinfection from other potential causes of strain differences.
Our results suggest that different strategies would be required to reduce tuberculosis recurrences in these 2 groups of patients. For HIV-uninfected patients (still the majority of tuberculosis cases in India), these may include vaccines to boost cell-mediated immune responses, intensification of regimens to ensure complete sterilization of lesions, and measures to improve treatment adherence. The American Thoracic Society guidelines recommend that, for those patients with cavitation on baseline chest X-ray or positive sputum cultures at 2 months, treatment should be extended to 9 months [37] . However, the Indian Tuberculosis Control program recommends 6-month treatment for all new patients with tuberculosis disease. Recent efforts in drug development suggest that it may be possible to develop treatment regimens (eg, using fluoroquinolones) that are more effective (as well as of shorter duration) than those that are currently available [38] . A real challenge is to ensure that patients complete 6 months of regular treatment because recurrence rates have been shown to correlate with adherence [37] . For HIV-infected patients, strategies to minimize recurrences would include longer treatment regimens, post-treatment prophylaxis (with 1 or 2 drugs), or initiation of antiretroviral treatment, thereby improving immune status and reducing susceptibility to new infections [39, 40] . Our study also highlights the importance of infection control in both the hospital and community settings, particularly in areas with high HIV prevalence.
In summary, our study has documented the differences in the nature of recurrences observed among HIV-infected and HIV-uninfected patients after successful treatment of tuberculosis disease in South India. Previous reports have been mainly from Africa; to the best of our knowledge, our data are the first from a tuberculosis-endemic country in Asia. These findings have implications for policy makers, as well as clinicians who manage patients with tuberculosis.
